Skip to main content

A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus

Abstract

Although corticosteroids and immunosuppressants are widely used for the treatments of systemic lupus erythematosus (SLE), safer and more effective therapies are prerequisite. We and others have reported that anti-CD20 antibody rituximab targeting B cells are effective for refractory SLE and, therefore, safety and clinical efficacy of rituximab in SLE was evaluated by a multicenter phase I/II clinical trial. An open-label, multicenter study of 15 patients with active and refractory SLE (total British Isles Lupus Assessment Group [BILAG] score 8 to 17) was conducted. Rituximab was administered to 5 SLE patients as 4 infusions of 500 mg/body every week and to 10 SLE patients as 2 infusions of 1000 mg/body every other week. Assessment of safety, infusion reactions and adverse effects was used as the primary outcome for clinical tolerability and was evaluated by 28 weeks. Rituximab was well tolerated, with most experiencing no significant adverse effects. B cells rapidly reduced in all patients and remained low until 6 months post-treatment. Four patients developed human antichimeric antibodies without affecting efficacy of rituximab. Changes in routine safety laboratory tests clearly related to rituximab were not observed. Nine among 14 evaluable patients achieved the major or partial clinical response of BILAG score and prednisolone dose significantly decreased at the 28 weeks. Rituximab therapy appears to be safe for the treatment of active SLE patients and holds significant therapeutic promise, at least for the majority of patients experiencing profound B-cell depletion.

This is a preview of subscription content, access via your institution.

References

  1. M Feldmann L Steinman (2006) ArticleTitleDesign of effective immunotherapy for human autoimmunity Nature 435 612–9 Occurrence Handle10.1038/nature03727

    Article  Google Scholar 

  2. JC Edwards G Cambridge (2006) ArticleTitleB-cell targeting in rheumatoid arthritis and other autoimmune diseases Nat Rev Immunol 6 394–403 Occurrence Handle16622478 Occurrence Handle10.1038/nri1838 Occurrence Handle1:CAS:528:DC%2BD28XjslOhu7g%3D

    Article  PubMed  CAS  Google Scholar 

  3. T Dorner (2006) ArticleTitleCrossroads of B-cell activation in autoimmunity: rationale of targeting B cells J Rheumatol Suppl 77 3–11 Occurrence Handle16652439

    PubMed  Google Scholar 

  4. CM Grimaldi R Hicks B Diamond (2005) ArticleTitleB-cell selection and susceptibility to autoimmunity J Immunol 174 1775–81 Occurrence Handle15699102 Occurrence Handle1:CAS:528:DC%2BD2MXhtV2ku78%3D

    PubMed  CAS  Google Scholar 

  5. RJ Looney (2006) ArticleTitleB cell-targeted therapy for rheumatoid arthritis: an update on the evidence Drugs 66 625–39 Occurrence Handle16620141 Occurrence Handle10.2165/00003495-200666050-00004 Occurrence Handle1:CAS:528:DC%2BD28XlsVCisbk%3D

    Article  PubMed  CAS  Google Scholar 

  6. JC Edwards L Szczepanski J Szechinski A Filipowicz-Sosnowka P Emery DR Close et al. (2004) ArticleTitleEfficacy of B cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 2572–81 Occurrence Handle15201414 Occurrence Handle10.1056/NEJMoa032534 Occurrence Handle1:CAS:528:DC%2BD2cXkvFKntrc%3D

    Article  PubMed  CAS  Google Scholar 

  7. P Emery R Fleischmann A Filipowicz-Sosnowska J Schechtman L Szczepanski A Kavanaugh et al. (2006) ArticleTitleDANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial Arthritis Rheum 54 1390–400 Occurrence Handle16649186 Occurrence Handle10.1002/art.21778 Occurrence Handle1:CAS:528:DC%2BD28XlsFSquro%3D

    Article  PubMed  CAS  Google Scholar 

  8. Y Tanaka (2006) ArticleTitleAnti-CD20 and other novel biotherapies for systemic lupus erythematosus APLAR J Rheumatol 9 413–8 Occurrence Handle10.1111/j.1479-8077.2006.00233.x

    Article  Google Scholar 

  9. MJ Leandro JC Edwards G Cambridge MR Ehrenstein DA Isenberg (2002) ArticleTitleAn open study of B lymphocyte depletion in systemic lupus erythematosus Arthritis Rheum 46 2673–7 Occurrence Handle12384926 Occurrence Handle10.1002/art.10541

    Article  PubMed  Google Scholar 

  10. MJ Leandro G Cambridge JC Edwards MR Ehrenstein DA Isenberg (2005) ArticleTitleB-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients Rheumatology 44 1542–5 Occurrence Handle16188950 Occurrence Handle10.1093/rheumatology/kei080 Occurrence Handle1:CAS:528:DC%2BD2MXht1GltrzP

    Article  PubMed  CAS  Google Scholar 

  11. RJ Looney JH Anolik D Campbell RE Felgar F Young LJ Arend et al. (2004) ArticleTitleB-cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab Arthritis Rheum 50 2580–9 Occurrence Handle15334472 Occurrence Handle10.1002/art.20430 Occurrence Handle1:CAS:528:DC%2BD2cXnsVKht7s%3D

    Article  PubMed  CAS  Google Scholar 

  12. PP Sfikakis JN Boletis S Lionaki V Vigklis KG Fragiadaki A Iniotaki et al. (2005) ArticleTitleRemission of proliferative lupus nephritis following B-cell depletion therapy is preceded by down-regulation of the T-cell costimulatory molecule CD40 ligand: an open-label trial Arthritis Rheum 52 501–13 Occurrence Handle15693003 Occurrence Handle10.1002/art.20858 Occurrence Handle1:CAS:528:DC%2BD2MXit1GjtLo%3D

    Article  PubMed  CAS  Google Scholar 

  13. RF van Vollenhoven I Gunnarsson E Welin-Henriksson B Sundelin A Osterborg SH Jacobson et al. (2004) ArticleTitleBiopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone Scand J Rheumatol 33 423–7 Occurrence Handle15794203 Occurrence Handle10.1080/03009740410010227 Occurrence Handle1:CAS:528:DC%2BD2MXmt1Gnug%3D%3D

    Article  PubMed  CAS  Google Scholar 

  14. K Saito M Nawata S Nakayamada M Tokunaga J Tsukada Y Tanaka (2003) ArticleTitleSuccessful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement Lupus 12 798–800 Occurrence Handle14596432 Occurrence Handle10.1191/0961203303lu450xx Occurrence Handle1:CAS:528:DC%2BD3sXptlCgt7k%3D

    Article  PubMed  CAS  Google Scholar 

  15. M Tokunaga K Fujii K Saito S Nakayamada S Tsujimura M Nawata et al. (2005) ArticleTitleDown-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab Rheumatology 44 176–82 Occurrence Handle15494350 Occurrence Handle10.1093/rheumatology/keh443 Occurrence Handle1:CAS:528:DC%2BD2MXovVynsA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  16. M Tokunaga K Saito D Kawabata Y Imura T Fujii S Nakayamada et al. (2007) ArticleTitleEfficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system Ann Rheum Dis 66 470–5 Occurrence Handle17107983 Occurrence Handle10.1136/ard.2006.057885 Occurrence Handle1:CAS:528:DC%2BD2sXkvFeks7w%3D

    Article  PubMed  CAS  Google Scholar 

  17. EM Tan AS Cohen JF Fries AT Masi DJ McShane NF Rothfield et al. (1982) ArticleTitleThe 1982 revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 25 1271–7 Occurrence Handle7138600 Occurrence Handle10.1002/art.1780251101 Occurrence Handle1:STN:280:BiyD2cfksFI%3D

    Article  PubMed  CAS  Google Scholar 

  18. EM Hay PA Bacon C Gordon DA Isenberg P Maddison ML Snaith et al. (1993) ArticleTitleThe BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus Q J Med 86 447–58 Occurrence Handle8210301 Occurrence Handle1:STN:280:ByuD383ovVM%3D

    PubMed  CAS  Google Scholar 

  19. DA Isenberg C Gordon (2000) ArticleTitleFrom BILAG to BLIPS. Disease activity assessment in lupus: past, present and future Lupus 9 651–4 Occurrence Handle11199918 Occurrence Handle10.1191/096120300672904669 Occurrence Handle1:STN:280:DC%2BD3M7kslentA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  20. Y Tanaka M Tokunaga (2006) ArticleTitleRituximab reduces both quantity and quality of B cells in SLE Rheumatology 45 122–3 Occurrence Handle10.1093/rheumatology/kei189 Occurrence Handle1:CAS:528:DC%2BD2MXhtlagtbjO

    Article  CAS  Google Scholar 

  21. I Sanz J Anolik (2005) ArticleTitleReconstitution of the adult B-cell repertoire after treatment with rituximab Arthritis Res Ther 7 175–6 Occurrence Handle16207341 Occurrence Handle10.1186/ar1799 Occurrence Handle1:CAS:528:DC%2BD2MXpvFOnsrk%3D

    Article  PubMed  CAS  Google Scholar 

  22. JH Anolik J Barnard A Cappione AE Pugh-Bernard RE Felgar RJ Looney et al. (2004) ArticleTitleRituximab improves peripheral B-cell abnormalities in human systemic lupus erythematosus Arthritis Rheum 50 3580–90 Occurrence Handle15529346 Occurrence Handle10.1002/art.20592 Occurrence Handle1:CAS:528:DC%2BD2cXhtVOqtrjK

    Article  PubMed  CAS  Google Scholar 

  23. MJ Leandro G Cambridge MR Ehrenstein JC Edwards (2006) ArticleTitleReconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis Arthritis Rheum 54 613–20 Occurrence Handle16447239 Occurrence Handle10.1002/art.21617 Occurrence Handle1:CAS:528:DC%2BD28XhvFKhsbg%3D

    Article  PubMed  CAS  Google Scholar 

  24. P Roll A Palanichamy C Kneitz T Dorner HP Tony (2006) ArticleTitleRegeneration of B-cell subsets after transient B-cell depletion using anti-CD20 antibodies in rheumatoid arthritis Arthritis Rheum 54 2377–86 Occurrence Handle16869000 Occurrence Handle10.1002/art.22019 Occurrence Handle1:CAS:528:DC%2BD28XpsFGgu7k%3D

    Article  PubMed  CAS  Google Scholar 

  25. GJ Silverman (2005) ArticleTitleAnti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic Arthritis Rheum 52 371–7 Occurrence Handle15692969 Occurrence Handle10.1002/art.20857

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yoshiya Tanaka.

About this article

Cite this article

Tanaka, Y., Yamamoto, K., Takeuchi, T. et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 17, 191–197 (2007). https://doi.org/10.1007/s10165-007-0565-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-007-0565-z

Key words

  • B cells
  • CD20
  • Monoclonal antibody
  • Rituximab
  • Systemic lupus erythematosus (SLE)